Although allogeneic HSCT may contribute to improve the inferior prognosis of MLL-R infant ALL, it was restricted to some patients because of early relapse before HSCT (Tomizawa et al., 2007). This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.